JP2025502861A5 - - Google Patents

Info

Publication number
JP2025502861A5
JP2025502861A5 JP2024540670A JP2024540670A JP2025502861A5 JP 2025502861 A5 JP2025502861 A5 JP 2025502861A5 JP 2024540670 A JP2024540670 A JP 2024540670A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2025502861 A5 JP2025502861 A5 JP 2025502861A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
sucrose
fxi
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502861A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/070573 external-priority patent/WO2023131213A1/zh
Publication of JP2025502861A publication Critical patent/JP2025502861A/ja
Publication of JP2025502861A5 publication Critical patent/JP2025502861A5/ja
Pending legal-status Critical Current

Links

JP2024540670A 2022-01-05 2023-01-05 抗FXI/FXIa抗体を含む医薬組成物及びその使用 Pending JP2025502861A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210006206.X 2022-01-05
CN202210006206 2022-01-05
CN202210053441 2022-01-18
CN202210053441.2 2022-01-18
PCT/CN2023/070573 WO2023131213A1 (zh) 2022-01-05 2023-01-05 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2025502861A JP2025502861A (ja) 2025-01-28
JP2025502861A5 true JP2025502861A5 (cg-RX-API-DMAC10.html) 2026-01-15

Family

ID=87073189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540670A Pending JP2025502861A (ja) 2022-01-05 2023-01-05 抗FXI/FXIa抗体を含む医薬組成物及びその使用

Country Status (6)

Country Link
US (1) US20250179213A1 (cg-RX-API-DMAC10.html)
EP (1) EP4461749A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025502861A (cg-RX-API-DMAC10.html)
CN (1) CN118382643A (cg-RX-API-DMAC10.html)
TW (1) TW202333789A (cg-RX-API-DMAC10.html)
WO (1) WO2023131213A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
PT3570882T (pt) * 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
RU2766590C2 (ru) * 2017-05-16 2022-03-15 Цзянсу Хэнжуй Медисин Ко., Лтд. Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2020008022A1 (en) * 2018-07-05 2020-01-09 Bayer Aktiengesellschaft METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
US12703762B2 (en) * 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
EP3957652A4 (en) * 2019-04-16 2023-06-21 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
JP2023507795A (ja) * 2019-12-20 2023-02-27 アントス セラピューティクス, インコーポレイテッド 第XI/XIa因子抗体の医薬製剤および投薬レジメン
BR112022026533A2 (pt) * 2020-07-02 2023-01-17 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo

Similar Documents

Publication Publication Date Title
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
TW201420601A (zh) 抗tslp抗體之安定調配物
JP2024508762A5 (cg-RX-API-DMAC10.html)
JP2024506940A5 (cg-RX-API-DMAC10.html)
JP2022532927A5 (cg-RX-API-DMAC10.html)
US12251474B2 (en) Process for lyophilized pharmaceutical formulations of a therapeutic protein
JP2017536414A5 (cg-RX-API-DMAC10.html)
US11498961B2 (en) SOST antibody pharmaceutical composition and uses thereof
CN110234353A (zh) 用于FXIa抗体的新型稳定制剂
WO2021127525A1 (en) Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
JP2024001135A (ja) Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
CN119677508A (zh) 与抗因子xi/因子xia抗体的组合疗法
KR20230035355A (ko) 인자 xii 항원 결합 단백질의 고농도 제형
JP2025506427A (ja) 生物学的製剤の経口送達のための組成物
WO1994022471A1 (fr) Preparation liquide d'antithrombine iii et procede pour sa stabilisation
JP2024508746A5 (cg-RX-API-DMAC10.html)
CN106459208B (zh) Tafi和pai-1的双重靶向
TW202333789A (zh) 一種包含抗FXI/FXIa抗體的醫藥組成物及其用途
JP2025521231A5 (cg-RX-API-DMAC10.html)
JP2024543931A5 (cg-RX-API-DMAC10.html)
RU2775692C2 (ru) Новые стабильные композиции для fxia антител
CN118078988A (zh) 包含靶向il-17a的抗体药物组合物
WO2023098694A1 (zh) 一种抗sost抗体药物组合物及其用途
RU2020102952A (ru) Фармацевтическая композиция, содержащая антитела к pcsk-9, и ее применение